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Background: With the rapid implementation of cystic fibrosis (CF) newborn screening (NBS), quality improvement (QI) has become essential to
identify and prevent errors. Using Process Failure Modes and Effects Analysis (PFMEA), we adapted this method to determine if it could be
applied to discover and rank high priority QI opportunities.
Methods: Site visits to three programmes were conducted, and PFMEA exercises were accomplished in Colorado, Massachusetts and Wisconsin
with 23 experienced professionals. During each of these comprehensive sessions, participants identified and ranked potential failures based on
severity, occurrence and detection to calculate risk priority number (RPN) values.
Results: A total of 96 failure modes were generated and ranked in a list of the 20 riskiest problems that show no significant discordances by site,
although there were differences by profession of the rater, particularly nurses.
Conclusions: Our results illustrate that the PFMEA method applies well to CF NBS and that steps requiring communication and information
transfer are perceived to be the highest risks. The number of identified failures makes and their potential impact demonstrate considerable overall
risk and a need for ongoing QI.
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“begin newborn screening (NBS) for cystic fibrosis (CF).” This
was endorsed [2] by the U.S. Cystic Fibrosis Foundation (CFF)
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only five states were then screening in the U.S., now all states
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doi:10.1016/j.jcf.2010.04.001During this rapid implementation, however, many questions
have arisen regarding best practices [3,5]. Until now, the most
common method for providing advice between programmes has
been by responding to questions and through anecdotes, usually
oral and occasionally published [6]. We recognized that this
verbal method of reactive quality improvement (QI) was cer-
tainly not themost effective way to communicate and that amore
proactive, systematic strategy would be preferable. Also, we
discovered that there was no description or assessment of the
entire CF NBS process.
To address these gaps, we proceeded to study and integrate
methods used in other industries. The Process FailureModes and
Effects Analysis (PFMEA) method was selected for its appli-
cability and because its primary goal is identifying problems
before they occur using a systematic method of critical analyses
[7] . More specifically, PFMEA allows preemptive recognition
of potential failures or errors. After being introduced in the lated by Elsevier B.V. All rights reserved.
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the aerospace industry during the 1960s, then in the automotive
industry [6], and finally into healthcare as the U.S Joint Com-
mission (JCAHO) added PFMEA use as a new requirement for
hospitals to be accredited [8,9]. In fact, there are more than 500
applications to health care improvement described by the Insti-
tute for Healthcare Improvement (IHI). These range from com-
puterized physician order entry to critical care. Although there
have been applications to newborns such as an “NICU Tracer
project with an aim to prevent breast milk administered to wrong
babies,” there is no example of application to newborn screen-
ing; see the IHI website for more data [http://www.ihi.org/ihi/
workspace/tools/fmea/AllTools.aspx]. Consequently, we organ-
ized a collaborative project to apply it with members of the
Colorado and Massachusetts CF NBS programmes and the
CDC.
1. Methods
Our strategy was to leverage the collective knowledge of
three long established and experienced CF NBS programmes
(Colorado, Massachusetts and Wisconsin, which collectively
have 62 years of experience with CF NBS) within the PFMEA
framework. We began by reviewing the literature, obtaining
advice from an automotive engineer, consulting with CDC, and
then completing an online course offered by Resource Engi-
neering, Inc. which describes the PFMEA method in detail
(www.reseng.com). Then, after carefully planning site visits to
each location, we conducted PFMEA exercises in 2007 and
2008, adapting the traditional ten step method (Table 1), whichTable 1
Ten steps for a PFMEA exercise a.
Step Action
1 Review the process and create a flowchart
2 List and critically examine potential failure modes
3 Describe potential effects of each failure mode including direct and
indirect effects
4 Assign severity ratings for each failure mode individually b
5 Assign occurrence ratings individually b
6 Assign detection ratings individually b
7 Determine the risk priority number (RPN) for each failure mode c
8 Establish an action plan
9 Take action to eliminate or reduce the high-risk failure mode
10 Calculate the new RPN as failure modes are reduced
a Adapted from “The Basics of FMEA” by McDermott et al. [7].
b A severity rating is a measure of how serious a given effect would be should
a failure occur, an occurrence rating is an estimate of how often failure modes
occur, and detection refers the “detectability” or the probability that the failure
will be detected before a problem ensues; estimates are based on the knowledge
and experience of the PMFEA team members or whenever possible on data
collected from the actual processes.
c RPN is the product of severity×occurrence×detection. Severity, occurrence,
and detection ratings range from 1 to 10, with 1 representing the least trouble-
some and 10 representing the most problematic. To aid in the discussion of
PFMEA teammembers regarding themeaning of each number between 1 and 10,
we used guides for orientation and standardization. For example, a severity rating
of 10 corresponds to “hazardous without warning: outcome likely to result in
death without warning” whereas a severity rating of 1 corresponds to “none: no
expected negative outcome”.can be divided into two phases: 1) identification of failure modes
and 2) development of an action plan; however, we chose to
focus on the first phase and while doing so identified QI oppor-
tunities. A total of 23 people participated in our three PFMEA
exercises, under the direction of the same team leader (RR, an
industrial engineer), and included NBS laboratory directors,
genetic counselors, nurses, physicians, epidemiologists, the
director of the NBS Branch of CDC, and the leader of the CDC
proficiency testing program.
Once the PFMEA teams at each location were established,
our first priority was to introduce participants to the PFMEA
process prior to the site visit. All team members were given a
document briefly explaining the PFMEA process along with
agendas. Each meeting began with the goal of first understand-
ing the entire PFMEA process by reviewing the ten steps and
illustrating them with a CF NBS flowchart. However, during
the planning phase of the PFMEA exercises it was determined
that a flowchart for CF NBS did not exist, so our team crafted
one for this purpose. Specifically, prior to the first site visit the
flowchart was drafted in Wisconsin; this task required as many
hours of work as each PFMEA site visit. Then, it was critically
reviewed/revised and finalized in Denver into a 3-component
flowchart available on a website [www.research.med.wisc.edu/
Farrell/]. The first section is for blood specimen collection, the
second for laboratory testing per se, and the final component
describes the steps for sweat testing and confirmation. Follow-
ing the creation of the flowchart, its validity and value were
confirmed independently in Boston.
At each site visit, we proceeded through to step #7, identi-
fying potential errors and assigning severity, occurrence, and
detection ratings to each failure mode in a range from 1 (lowest)
to 10. The PFMEA team members were instructed carefully in
how they should decide what number to assign for each cate-
gory using tables and examples such as the guidelines provided
in Table 2 for detection ratings. Finally, the three numbers wereTable 2
Guidelines (instructions) for assignment of detection ratings a.
Scale for rating the probability of detecting a failure mode:
10 Almost impossible: almost never discovered (e.g., a missed baby who dies of
CF, i.e., infant with a false negative NBS result followed by fatal
hyponatremic/hypochloremic dehydration)
9 Very remote: unlikely to discover without extraordinary means
8 Remote: unlikely to discover without significant effort (e.g., a sick baby
transferred on day 1 to a Neonatal ICU who does not have a NBS screening
blood collection performed)
7 Very low: unlikely to discover without moderate effort
6 Low: difficult to discover quickly but likely to discover over longer term (e.g.,
false negative sweat test result, assuming that it is likely to be repeated)
5 Moderate: requires moderate detection to discover
4 Moderately high: likely to discover in a moderate time period with moderate
effort (e.g., specimen is exposed to adverse conditions during transport to
screening laboratory)
3 High: nearly sure to discover in a moderate time period with moderate effort
2 Very high: discovered quite easily (e.g., DNA panel is not appropriate for
ethnic population being screened with IRT/DNA)
1 Almost certain to detect: discovered quickly and easily
a Adapted from “The Basics of FMEA” by McDermott et al. [7].
Table 3
Top 20 failure modes determined by the relative ratings (RPN values) assigned
by site.
Rank Failure mode RPNa
1 Parents misunderstand genetic counseling information 203.0
2 Hospital system may not screen baby if transferred immediately
(i.e., to NICU, other hospital, etc)
180.1
3 Low IRT cutoff in laboratory leads to a false negative 164.9
4 Babies with similar names are confused leading to sample
mix-up or reporting mix-up
159.6
5 PCP b who tells results to parents is not well-trained about what
results truly mean
158.8
6 Clerical error (i.e., hospital or laboratory transcribes data or
results incorrectly)
158.2
7 PCP b who tells results to parents is inconsistent in delivery of
results to parents (i.e., not scripted)
157.3
8 Baby is not ever tested (i.e., baby born outside of medical
system, parents refuse, etc)
153.3
9 Nurse/lab technician picks up wrong NBS card (i.e.: handling
error in hospital, nursery or lab)
153.2
10 False negative outcome (i.e., baby has CF but results of IRT,
DNA and/or sweat Cl indicate no CF)
148.4
11 No script for message to PCPb from lab about positive test result
(i.e., may be misunderstood by PCPb)
146.6
12 Multiple babies have blood drawn in assembly line process
(ie: babies may be switched/confused)
139.9
13 Mother does not comprehend information provided on NBS due 139.5
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rating which then can be used to determine the relative ranking
of the failure modes [7]. A recent dramatic example from the
automotive industry, the problem of “unintended-acceleration”
illustrates the RPN calculation process: the risk severity (severe
injury or even death) is high (9–10) but it is a relatively infre-
quent failure (∼2000 cars out of millions sold, which might be
a 1–2 rating); however, there is one easily detectable cause
(a trapped floor mat which might be a 1–2 rating) and one
nearly undetectable cause (mechanical failure—a rating of 9–
10 on the RPN scale).
RPN values for each site were calculated by summing RPNs
from each member and then dividing by the total number of
members at that site. McNemar's test was used to examine the
ranking concordance between each pair of the three sites by
converting their original rankings into binary responses (i.e.,
≤10 or N10; either ≤20 or N20). The overall RPNs were cal-
culated with each site equal weighted. A list of 20 failure modes
with the highest RPNs was then generated. Effects of sites and
professions on RPNs were examined by general linear models.
t tests were used to compare RPNs between sites and between
professions. Least square means, which adjust for the potential
effects of sites and professions, were produced.to language, intellect, delivery method, etc
14 Clinician assisting in delivery does not inform parents about
NBS requirement
133.0
15 Specimen is exposed to adverse conditions during transport to lab 127.4
16 False negative sweat test from a baby with only one detectable
mutation
125.0
17 Clinician assisting in delivery is unaware of NBS requirement 123.7
18 DNA panel is not appropriate for racial, ethnic population being
screened
122.2
19 Genetic counseling is insensitive/ineffective regarding lab and
sweat test results
120.7
20 All personnel involved in NBS process are not adequately trained 118.5
a Risk priority number (product of perceived severity×occurrence probability×
detectability).
b Primary care provider.2. Results
After a thorough review of the CF NBS program in Wis-
consin, a 3-component flowchart was drafted to include both the
IRT/IRT and IRT/DNA algorithms. This was refined, finalized
by consensus, and used at the first site visit in Colorado and then
confirmed/used at the Massachusetts and Wisconsin site visits.
During the three PFMEA exercise sessions, we identified a total
of 96 potential failure modes throughout the entire CF NBS
process. The three-site mean RPN values (failure mode severity×
occurrence probability×detectability) for all the failure modes
ranged from 15.5 to 203.0. The RPN values varied by site
(pb .0001), possibly due to differences in screening protocols
and experiences. From the same overall general linear model,
there were also significant differences among professions (p=
.0013) due to assignment of lower RPN values by the nurses
who were lower than both laboratory personnel (p=.0005) and
physicians (p=.035); more specifically, the nurses rated sig-
nificantly lower on severity and occurrence (pb .0001) but not
on the detection scale (p=.89).
On the other hand, despite the differences among sites in the
magnitude of RPN ratings, the rankings were similar for the 20
items determined to be of greatest concern (Table 3). In fact,
there was no statistically significant discordance between sites
for the top 20 failure modes. They had RPN values over 118,
which would be alarming in other industries, and occurred at
many different steps in the CF NBS process. However, in what
must be considered our most noteworthy finding, 14 of the 20
potential failures relate to communication and/or information
transfer. Documentation of all the failure modes and the unique
3-component NBS flowchart can be downloaded at www.
research.med.wisc.edu/farrell/.3. Conclusions
These results illustrate that the PFMEA method applies well
to the CF NBS process. We were able to create a system-wide
CF NBS flowchart, to successfully identify 96 potential failures,
as well as rank them by their relative risk, and then to determine
which problems require the most immediate attention or were
most worrisome. Similar results in ranking the top 20 failure
modes were reached at all three locations illustrating both the
successful application of the PFMEA method as well as valid-
ating the highest ranking failure modes. Upon further review
of the top 20 failure modes, it becomes abundantly clear that
communication and information transfer are the weak links in
the CF NBS process. Well over half of the top 20 failure modes
are directly related to communication between two different
parties while the remaining failure modes could arguably be
indirectly related to communication or information transfer.
This illustrates the importance of consistency and standardiza-
tion of communication when possible as well as checks to
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While communication is resounding theme, other failure modes
including technical errors and sample processing errors should
not be minimized.
Since our goal was to determine the applicability of PFMEA
methods to NBS as well as develop a preliminary list of poten-
tial failure modes, we have not yet fully addressed PFMEA
steps 8, 9, and 10 (development, implementation and follow-up
of an action plan), although we discussed QI options at each
site. In industries such as automobile manufacturing, the PFMEA
team first identifies the failure modes with high RPN values
(e.g., the “unintended- acceleration” problem recently encoun-
tered with Toyota vehicles) and then assignments are made to
different QI teams to devise and study methods that will reduce
or hopefully eliminate the potential failure. Accordingly, Phase
II must follow in a focused fashion addressing the identified/
prioritized failure modes item-by-item. However, we can briefly
preview this next phase and consider corrective actions, which
should involve error proofing whenever possible. For instance,
the second ranked failure mode (“hospital systemmay not screen
baby if transferred immediately”) has recently been addressed by
development of new policy guidelines [10] that recommend
assured collection of newborn screening blood “upon admis-
sion” to the NICU and on two other occasions.
Another example involves the 16th ranked failure mode
(“false negative sweat test. . .”). This is also being addressed by
new procedural guidelines recently published [11] by the Clini-
cal Laboratory Standards Institute, as well as by a concerted
effort on the part of the U.S. Cystic Fibrosis Foundation. Be-
cause error proofing is not always possible, however, our study
provides insight to another avenue through which the RPN
values could be lowered: enhancement of detection. We believe
focusing on detection is ideal because severity is unalterable
and frequency can only be minimized to a limited extent. For
example, to enhance detection of the first failure mode (“parents
misunderstand genetic counseling information”) parental under-
standing could be assessed routinely immediately following and
several months after counseling sessions [12,13]. In addition, in-
formation transfer can be standardized [14]. In general, the aero-
space, aviation, and automotive industries also place emphasis
on improving detection for QI (e.g., tire pressure monitoring). In
the future, CF NBS professionals should follow-up on this strat-
egy by creating solutions and tools that address these problem
areas starting with the highest ranked items and disseminating
potential solutions widely.
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